neuroendocrine
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
James C. Yao Chair, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours. | Neuroendocrine tumours | none | mtor, trialist | ||
Jennifer A. Chan Clinical Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed. | Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Lung neuroendocrine tumours | none | targeted-therapy, trialist | ||
Jonathan R. Strosberg Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center · Moffitt Cancer Center Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours. | Neuroendocrine tumours | none | radioligand, trialist | ||
Martyn E. Caplin Professor of Gastroenterology and Neuroendocrine Tumours, Royal Free Hospital and UCL · Royal Free Hospital, Royal Free London NHS Foundation Trust Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs. | Neuroendocrine tumours | none | somatostatin, uk | ||
Simron Singh Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre · Sunnybrook Odette Cancer Centre Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours. | Neuroendocrine tumours | none | radioligand, canada |